Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Cancer Immunology, Immunotherapy : CII|September 14, 2016
Potential use of lymph node-derived HPV-specific T cells for adoptive cell therapy of cervical cancerMariëtte I E van Poelgeest, Valeria V Visconti, Zohara Aghai, et al.
International Journal of Cancer|October 4, 2025
Impact of geriatric impairments on outcomes of single-agent immunotherapy in solid tumorsAsli Özkan, Karlijn de Joode, Ellen Kapiteijn, et al.
European Journal of Cancer (Oxford, England : 1990)|June 25, 2025
Impact of immune-related adverse events on quality of life and physical functioning in older patients with solid tumors treated with immune checkpoint inhibitorsAsli Özkan, Karlijn de Joode, Ellen Kapiteijn, et al.
Molecular Therapy Oncolytics|November 3, 2023
Erratum: A library of cancer testis specific T cell receptors for T cell receptor gene therapyMarije A J de Rooij, Dennis F G Remst, Dirk M van der Steen, et al.
Molecular Therapy Oncolytics|January 2, 2023
A library of cancer testis specific T cell receptors for T cell receptor gene therapyMarije A J de Rooij, Dennis F G Remst, Dirk M van der Steen, et al.
Nature|June 29, 2016
Neoantigen landscape dynamics during human melanoma-T cell interactionsEls M E Verdegaal, Noel F C C de Miranda, Marten Visser, et al.
Journal for Immunotherapy of Cancer|June 30, 2024
Autoantibody-positivity before and seroconversion during treatment with anti-PD-1 is associated with immune-related adverse events in patients with melanomaJessica S W Borgers, Tineke J van Wesemael, Kyra A Gelderman, et al.
Genome Medicine|January 1, 2020
Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4Jitske van den Bulk, Els M E Verdegaal, Dina Ruano, et al.
Frontiers in Immunology|April 7, 2023
PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancerRosa A van Amerongen, Sander Tuit, Anne K Wouters, et al.
Chembiochem : a European Journal of Chemical Biology|November 12, 2020
Simplified Monopalmitoyl Toll-like Receptor 2 Ligand Mini-UPam for Self-Adjuvanting Neoantigen-Based Synthetic Cancer VaccinesThomas C van den Ende, Jeroen M M Heuts, Geoffroy P P Gential, et al.
Pageof 4